

10/085,612

(FILE 'HOME' ENTERED AT 09:48:50 ON 03 OCT 2003)

FILE 'MEDLINE, CANCERLIT, LIFESCI, SCISEARCH, EMBASE, BIOSIS, CAPLUS'  
ENTERED AT 09:49:06 ON 03 OCT 2003

- E GUIDA M/AU
- L1 644 SEA "GUIDA M"/AU OR "GUIDA MARCO"/AU  
E HALL J/AU
- L2 2902 SEA "HALL J"/AU  
E HALL JEFF/AU
- L3 36 SEA "HALL JEFF"/AU  
E PETROS W/AU
- L4 393 SEA "PETROS W"/AU OR "PETROS W P"/AU OR "PETROS WILLIAM"/AU  
OR  
"PETROS WILLIAM P"/AU  
E VREDENBURGH J/AU
- L5 467 SEA "VREDENBURGH J"/AU OR "VREDENBURGH J J"/AU OR  
"VREDENBURGH  
JAMES"/AU OR "VREDENBURGH JAMES J"/AU  
E COLVIN O M/AU
- L6 713 SEA "COLVIN O"/AU OR "COLVIN O M"/AU OR "COLVIN OLIVER M"/AU  
E MARKS J M/AU
- L7 282 SEA "MARKS J M"/AU  
E MARKS J R/AU
- L8 377 SEA "MARKS J R"/AU  
E MARKS JEFFREY R/AU
- L9 101 SEA "MARKS JEFFREY R"/AU
- L10 13485 SEA (CYP3A4 OR CYP 3A4 OR P450 3A4 OR P 450 3A4 OR CYP3A4 OR  
CYP 3A4 OR P4503A4 OR P450 3A4 OR P 450 3A4)
- L11 257 SEA L10 AND (POLYMORPHISM OR VARIANT OR MUTATION OR  
ALLEL####)  
AND(PROMOTER OR UPSTREAM OR REGULAT#####)
- L12 416 SEA (CYP3P5 OR CYP 3A5 OR P450 3A5 OR P 450 3A5 OR CYP3A5 OR  
CYP 3A5 OR P4503A5 OR P450 3A5 OR P 450 3A5)
- L13 28 SEA L12 AND (POLYMORPHISM OR VARIANT OR MUTATION OR  
ALLEL####)  
AND(PROMOTER OR UPSTREAM OR REGULAT#####)
- L14 2878 SEA (GSTM1 OR GLUTATHIONE S TRANSFERASE M1 OR  
GLUTATHIONE  
STRANSFERASE M1) AND NULL
- L15 6 SEA (L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L8 OR L9) AND (L11 OR  
L13 OR L14)
- L16 4 DUP REM L15 (2 DUPLICATES REMOVED)
- L17 27 SEA (CYCLOPHOSPHAMIDE) AND (L11 OR L12 OR L14)
- L18 17 DUP REM L17 (10 DUPLICATES REMOVED)
- L19 21 SEA (CYCLOPHOSPHAMIDE) AND (L11 OR L13 OR L14)

L20 11 DUP REM L19 (10 DUPLICATES REMOVED)  
 L21 6 SEA (CARMUSTINE OR BCNU OR BICNU OR NITROSOUREA) AND (L11  
 OR  
 L13 OR L14)  
 L22 5 DUP REM L21 (1 DUPLICATE REMOVED)  
 L23 46 SEA L11 AND (SUBSTRATE OR CHEMOTHERAP##### OR AGENT)  
 L24 24 DUP REM L23 (22 DUPLICATES REMOVED)  
 L25 7 SEA L13 AND (SUBSTRATE OR CHEMOTHERAP##### OR AGENT)  
 L26 5 DUP REM L25 (2 DUPLICATES REMOVED)  
 L27 189 SEA L14 AND (SUBSTRATE OR CHEMOTHERAP##### OR AGENT)  
 L28 72 DUP REM L27 (117 DUPLICATES REMOVED)  
 L29 66 SEA L11 AND (HOMOZYGOUS OR HETEROZYGOUS)  
 L30 16 SEA L11 AND RESTRICTION  
 L31 8 SEA L29 AND L30  
 L32 3 DUP REM L31 (5 DUPLICATES REMOVED)  
 L33 11 SEA L13 AND (HOMOZYGOUS OR HETEROZYGOUS)  
 L34 2 SEA L13 AND RESTRICTION  
 L35 0 SEA L33 AND L34  
 L36 2 DUP REM L34 (0 DUPLICATES REMOVED)  
 L37 6 DUP REM L33 (5 DUPLICATES REMOVED)  
 L38 0 SEA L13 AND 147  
 L39 650 SEA L14 AND (HOMOZYGOUS OR HETEROZYGOUS)  
 L40 215 SEA L14 AND RESTRICTION  
 L41 33 SEA L39 AND L40  
 L42 12 DUP REM L41 (21 DUPLICATES REMOVED)

## WEST Search History

DATE: Friday, October 03, 2003

### Set Name Query

side by side

### Hit Count Set Name

result set

*DB=USPT,PGPB,DWPI; PLUR=YES; OP=ADJ*

L11	L10 not (18 or 19)	16	L11
L10	(15 or 16 or 17) and (substrate or chemotherap\$6 or agent)	20	L10
L9	(15 or 16 or 17) and (carmustine or bcnu or bicnu or nitrosoarea)	3	L9
L8	(15 or 16 or 17) and cyclophosphamide	4	L8
L7	(gstml or glutathione s transferase m1 or glutathione stransferase m1)same(null)	6	L7
L6	14 same (polymorphism or mutation or variant or allele\$4) same (promoter or upstream or regulator\$5)	7	L6
L5	13 same (polymorphism or mutation or variant or allele\$4) same (promoter or upstream or regulator\$5)	17	L5
L4	(cyp3a5 or cyp 3a5 or p450 3a5 or p 450 3a5 or cypiiia5 or cyp iiia5 or p450iiia5 or p450 iiia5 or p 450 iiia5)	59	L4
L3	(cyp3a4 or cyp 3a4 or p450 3a4 or p 450 3a4 or cypiiia4 or cyp iiia4 or p450iiia4 or p450 iiia4 or p 450 iiia4)	439	L3
L2	(guida-m\$.in. or hall-j\$.in. or petros-w\$.in. or vredenburgh-j\$.in. or colvin-o\$.in. or marks-j\$.in.)	2609	L2
L1	'DUKE UNIVERSITY INC.'	0	L1

END OF SEARCH HISTORY

# National Library of Medicine - Medical Subject Headings

2003 MeSH

## MeSH Descriptor Data

[Return to Entry Page](#)

<b>MeSH Heading</b>	Cyclophosphamide
<b>Tree Number</b>	D02.455.526.728.650.730.243
<b>Tree Number</b>	D02.705.670.243
<b>Scope Note</b>	Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active <u>ALDOPHOSPHAMIDE</u> . It is used in the treatment of lymphomas, leukemias, etc. Its side effect, <u>ALOPECIA</u> , has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
<b>Entry Term</b>	B-518
<b>Entry Term</b>	Cyclophosphamide Monohydrate
<b>Entry Term</b>	Cyclophosphamide, (+-)-Isomer
<b>Entry Term</b>	Cyclophosphamide, (R)-Isomer
<b>Entry Term</b>	Cyclophosphamide, (S)-Isomer
<b>Entry Term</b>	Cyclophosphane
<b>Entry Term</b>	Cytosphan
<b>Entry Term</b>	Cytosan
<b>Entry Term</b>	Endoxan
<b>Entry Term</b>	NSC-26271
<b>Entry Term</b>	Neosar
<b>Entry Term</b>	Procytox
<b>Entry Term</b>	Sendoxan
<b>Allowable Qualifiers</b>	AA AD AE AG AI AN BL CF CH CL CS CT DU EC HI IM IP ME PD PK PO RE SD ST TO TU UR
<b>Pharm. Action</b>	Antineoplastic Agents, Alkylating
<b>Pharm. Action</b>	Antirheumatic Agents
<b>Pharm. Action</b>	Immunosuppressive Agents
<b>Pharm. Action</b>	Mutagens
<b>CAS Type 1 Name</b>	2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide

# National Library of Medicine - Medical Subject Headings

2003 MeSH

## MeSH Descriptor Data

[Return to Entry Page](#)

<b>MeSH Heading</b>	Carmustine
<b>Tree Number</b>	<a href="#">D02.654.692.247</a>
<b>Tree Number</b>	<a href="#">D02.948.594.247</a>
<b>Scope Note</b>	A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
<b>Entry Term</b>	BCNU
<b>Entry Term</b>	1,3-Bis(2-Chloroethyl)-1-Nitrosourea
<b>Entry Term</b>	BiCNU
<b>Entry Term</b>	FIVB
<b>Entry Term</b>	N,N'-Bis(2-Chloroethyl)-N-Nitrosourea
<b>Entry Term</b>	Nitrumon
<b>Allowable Qualifiers</b>	<a href="#">AA</a> <a href="#">AD</a> <a href="#">AE</a> <a href="#">AG</a> <a href="#">AI</a> <a href="#">AN</a> <a href="#">BL</a> <a href="#">CF</a> <a href="#">CH</a> <a href="#">CL</a> <a href="#">CS</a> <a href="#">CT</a> <a href="#">DU</a> <a href="#">EC</a> <a href="#">HI</a> <a href="#">IM</a> <a href="#">IP</a> <a href="#">ME</a> <a href="#">PD</a> <a href="#">PK</a> <a href="#">PO</a> <a href="#">RE</a> <a href="#">SD</a> <a href="#">ST</a> <a href="#">TO</a> <a href="#">TU</a> <a href="#">UR</a>
<b>Pharm. Action</b>	Antineoplastic Agents, Alkylating
<b>CAS Type 1 Name</b>	Urea, N,N'-bis(2-chloroethyl)-N-nitroso-
<b>Registry Number</b>	154-93-8
<b>Previous Indexing</b>	<a href="#">Alkylating Agents</a> (1966-1971)
<b>Previous Indexing</b>	<a href="#">Nitroso Compounds</a> (1966-1971)
<b>Previous Indexing</b>	<a href="#">Urea</a> (1966-1971)
<b>History Note</b>	73(72)
<b>Unique ID</b>	D002330

## MeSH Tree Structures